Novo Nordisk and Biomarin make peace in strife over employees and confidentiality

A court strife between Novo Nordisk and Biomarin on business secrets and the recruitment of central Novo Nordisk employees has been concluded outside of court, according to Børsen.

Photo: Stine Tidsvilde

Novo Nordisk and the US-based biotech firm Biomarin have settled their court fight in the battle for the hemophilia market, according to Danish newspaper Børsen.

The strife revolves around the former Novo CEO's sales of hemophilia treatments on the US east coast. James Stephens moved to Biomarin in fall 2019, and Novo Nordisk feared Stephens had taken confidential documents to his new employer. Furthermore, it was convinced that Biomarin had attempted to hire Stephens – and other salespeople from the Danish firm – precisely because of the confidential knowledge which they were in possession of on the hemophilia market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs